Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 5/20 | 0.31 |
| ▸ | ACE | P12821 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394954 | 0.81 | TGFBR1 (0.36) | OR51E2MMP1TGFBR1MMEACE | |
| SCHEMBL23855055 | 0.81 | TGFBR1 (0.36) | OR51E2MMP1TGFBR1MMEACE | |
| SCHEMBL4595646 | 0.81 | MME (0.34) | MMP1TGFBR1MMELMNA | |
| SCHEMBL1529699 | 0.75 | NPC1 (0.45) | MMEACE | |
| SCHEMBL3910231 | 0.74 | LAP3 (0.41) | LMNA | |
| SCHEMBL1132971 | 0.74 | MEN1 (0.31) | TGFBR1 | |
| SCHEMBL3914911 | 0.72 | SLC1A2 (0.37) | — | |
| SCHEMBL3157408 | 0.72 | TGFBR1 (0.32) | TGFBR1 | |
| SCHEMBL3156097 | 0.72 | TGFBR1 (0.32) | TGFBR1 | |
| SCHEMBL3899245 | 0.71 | GRN (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| US-8980322-B2 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8722084-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2283827-A1 | Controlled release preparation | Takeda Pharmaceutical Company Limited (JP) | 2011-02-16 | — | — | EP | disclosed |
| EP-2277510-A2 | Controlled release preparation | Takeda Pharmaceutical Company Limited (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-20100278911-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| US-7410981-B2 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20050222210-A1 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222210-A1 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | SI, VIP, PGC | OR51E2 4769/4885PDE4A 1064/4885MMP1 1062/4885 |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | OR51E2 3295/4885PDE4A 1741/4885MMP1 816/4885 |
| US-20100278911-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | OR51E2 3295/4885PDE4A 1741/4885MMP1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.